Benzingaยท2025-09-22 13:09Core Viewpoint - Pfizer Inc. has agreed to acquire Metsera, Inc. to enhance its capabilities in developing next-generation medicines for obesity and cardiometabolic diseases, indicating a strategic move into a significant therapeutic area [1][2]. Group 1: Acquisition Details - Pfizer will acquire Metsera for $47.50 per share in cash, leading to an enterprise value of approximately $4.9 billion [2][3]. - The agreement includes potential milestone payments of up to $22.50 per share in cash [3]. - The transaction is expected to close in the fourth quarter of 2025 [3]. Group 2: Metsera's Pipeline - Metsera has a portfolio of therapeutic candidates, including four programs currently in clinical development [2]. - The pipeline features MET-097i, a weekly and monthly injectable GLP-1 receptor agonist in Phase 2 development, and MET-233i, a monthly amylin analog candidate [5]. - Additionally, there are two oral GLP-1 RA candidates set to begin clinical trials and other preclinical nutrient-stimulated hormone therapeutics [5]. Group 3: Market Context - The obesity market is significant, with over 200 health conditions associated with it, highlighting the potential for growth in this therapeutic area [1]. - Following the discontinuation of danuglipron, Pfizer aims to re-enter the next-generation anti-obesity drug sector through this acquisition [3].